The initial public offering (IPO) of Anthem Biosciences on its second day of bidding process, subscribed 3.29 times, with total bids received for 14,48,55,464 shares against 4,40,70,682 shares on offer, according to BSE data.
The Qualified Institutional Buyers (QIBs) segment received bids for 74,06,464 shares against 1,25,43,518 shares on offer, translating to a subscription of 0.59 times. Meanwhile, the Non-Institutional Investors (NIIs) category showed strong interest, with a subscription of 9.72 times, receiving bids for 9,14,33,680 shares against 94,07,639 shares available.
The Retail Individual Investors (RIIs) segment showed robust participation, with bids for 4,55,81,198 shares against 2,19,51,158 shares, resulting in a 2.08 times subscription.The IPO bidding window will close on Wednesday, July 16.
Anthem Biosciences IPO: Day 1 subscription
On the first day of bidding, the issue was subscribed 0.73 times, with investors placing bids for 3.21 crore shares against 4.40 crore shares available, as per BSE data. Before the IPO opened, the company allotted 1.78 crore shares to 60 anchor investors at Rs 570 each, which is the highest price in the IPO range.
Anthem Biosciences IPO: Should you apply? Here’s what Anil Singhvi suggests
Zee Business Managing Editor Anil Singhvi has given a positive view on the IPO. He advised investors to apply for both listing gains and to hold the stock for 2-3 years as a long-term investment. “Apply for good listing gain and long term. This stock should be in your pharma portfolio for 2-3 years,” he said.
Also Read: Anthem Biosciences raises Rs 1,016 crore from anchor investors ahead of IPO
What works in company’s favour:
- Experienced and professional promoters
- Market leader in CRDMO (contract research and manufacturing)
- Track record of successful drugs
- Long-term relationships with clients
- Strong financials, positive cash flow, and very low debt
- Better financials compared to listed competitors
- While smaller than Divi’s Laboratories in size, it matches in quality
Risks and concerns:
- Heavy dependence on one client (Davos Pharma contributes 14 per cent of revenue)
- R&D spending has been falling
- Growth depends on the success of new drug molecules
- Valuation is fair — not too cheap, not too expensive
Anthem Biosciences IPO details: Price, lot size, and financial performance
This IPO is an Offer for Sale (OFS), meaning the money raised will go to existing promoters and investors, not the company. The price band has been set at Rs 540 to Rs 570 per share. Investors can apply for a lot of 26 shares and in multiples of that.
In terms of financials, the company posted a 30 per cent rise in revenue from Rs 1,419 crore in FY24 to Rs 1,844 crore in FY25. Net profit also increased by 23 per cent to Rs 451 crore.
Industry competitors
Anthem Biosciences operates in the pharma and biotech space. Its listed peers include Sai Life Sciences, Syngene International, Suven Life Sciences, and Divi’s Laboratories.
